Journal article

Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity

Arturo Reyes-Sandoval, Christine S Rollier, Anita Milicic, Karolis Bauza, Matthew G Cottingham, Choon-Kit Tang, Matthew D Dicks, Dong Wang, Rhea J Longley, David H Wyllie, Adrian VS Hill

Molecular Therapy | CELL PRESS | Published : 2012

University of Melbourne Researchers


Awarded by Wellcome Trust

Funding Acknowledgements

We thank the Jenner Institute's vector core facility for providing the viral-vectored vaccines and Dr Helen McShane for providing the adenoviral and MVA vectors expressing antigen 85A. We are also grateful to Andrew Williams for providing the P. berghei parasites and the NIH tetramer facility (MHC tetramer core facility, Emory University Vaccine Center, Atlanta, GA) for preparing the Pb9 tetramer. The transgenic parasites were kindly provided by Dr Oliver Billker from Wellcome Trust Sanger Institute, Hinxton, UK. This work was funded by Wellcome Trust Principal Research Fellowship award; Grant Number: 076438; The National Institute for Health Research Oxford Biomedical Research Centre Program and Grand Challenges in Global Health. A.R.-S. is a Scientific Leadership Fellow of the Nuffield Department of Medicine and a Wellcome Trust Fellow. C. S. R. is supported by Oxford Biomedical Research Center, The Oxford Martin School and Meningitis UK.